Next Article in Journal
Loss of miR-107, miR-181c and miR-29a-3p Promote Activation of Notch2 Signaling in Pediatric High-Grade Gliomas (pHGGs)
Next Article in Special Issue
Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas
Previous Article in Journal
Insights into the Structural Requirements of Potent Brassinosteroids as Vegetable Growth Promoters Using Second-Internode Elongation as Biological Activity: CoMFA and CoMSIA Studies
Previous Article in Special Issue
Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models

Role of Galectins in Multiple Myeloma

Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, Italy
Hematology, “Azienda Ospedaliero-Universitaria di Parma”, Via Gramsci, 14, 43126 Parma, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(12), 2740;
Received: 29 November 2017 / Revised: 11 December 2017 / Accepted: 12 December 2017 / Published: 17 December 2017
(This article belongs to the Special Issue Galectins in Cancer and Translational Medicine)
Galectins are a family of lectins that bind β-galactose-containing glycoconjugates and are characterized by carbohydrate-recognition domains (CRDs). Galectins exploit several biological functions, including angiogenesis, regulation of immune cell activities and cell adhesion, in both physiological and pathological processes, as tumor progression. Multiple myeloma (MM) is a plasma cell (PC) malignancy characterized by the tight adhesion between tumoral PCs and bone marrow (BM) microenvironment, leading to the increase of PC survival and drug resistance, MM-induced neo-angiogenesis, immunosuppression and osteolytic bone lesions. In this review, we explore the expression profiles and the roles of galectin-1, galectin-3, galectin-8 and galectin-9 in the pathophysiology of MM. We focus on the role of these lectins in the interplay between MM and BM microenvironment cells showing their involvement in MM progression mainly through the regulation of PC survival and MM-induced angiogenesis and osteoclastogenesis. The translational impact of these pre-clinical pieces of evidence is supported by recent data that indicate galectins could be new attractive targets to block MM cell growth in vivo and by the evidence that the expression levels of LGALS1 and LGALS8, genes encoding for galectin-1 and galectin-8 respectively, correlate to MM patients’ survival. View Full-Text
Keywords: galectins; myeloma; galectin-1; galectin-3; galectin-8; galectin-9 galectins; myeloma; galectin-1; galectin-3; galectin-8; galectin-9
Show Figures

Figure 1

MDPI and ACS Style

Storti, P.; Marchica, V.; Giuliani, N. Role of Galectins in Multiple Myeloma. Int. J. Mol. Sci. 2017, 18, 2740.

AMA Style

Storti P, Marchica V, Giuliani N. Role of Galectins in Multiple Myeloma. International Journal of Molecular Sciences. 2017; 18(12):2740.

Chicago/Turabian Style

Storti, Paola, Valentina Marchica, and Nicola Giuliani. 2017. "Role of Galectins in Multiple Myeloma" International Journal of Molecular Sciences 18, no. 12: 2740.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop